ACTL6A and cancer: Similarly, siRNA- and shRNA-transfected HNC cell lines have shown promising results for downregulating ACTL6A expressions (Liu et al., 2024; Dang et al., 2020; Saladi et al., 2017); these findings offer hope for tackling chemoresistance in cancer therapy.